Signature STb — Fast, focused, actionable.
Urgent intelligence for immediate decisions.
When time is your most critical asset, you cannot wait weeks for a massive report, nor sift through data on drugs that are not available in India. Signature STb is our high-speed, highly focused liquid biopsy. From a simple blood draw, it analyses a precise set of 33 uniquely actionable genes with speed and precision.
Built for urgent scenarios, it strips away the noise — looking only at the genetic drivers and fusions that have targeted therapies approved, accessible, and actionable in India today.
₹1,50,000 — panel + execution bundle
The price includes the testing panel and the execution bundle: the Blueprint Care decision report with three months of care coordination, plus an in-person KPCIRC molecular tumour board review.
- 33 genes: Directly-actionable drivers with drugs accessible in India
- 13 fusions: Clinically actionable rearrangements
- Immune profile: TMB & MSI via a 200+ gene adhoc test
- PGx panel: 35-gene pharmacogenomics & drug-response profile
- Blueprint Care: 3 months of care coordination included
Three reasons to choose Signature STb.
When you need an answer now — and every positive result needs to be actionable.
Urgent Turnaround
When your doctor needs an answer now to start first- or second-line treatment, this focused panel cuts through the computational heavy lifting.
100% Actionable Focus
Every gene tested has a direct, approved drug or an accessible clinical trial linked to it in India — so every positive result comes with a real-world option.
Non-Invasive
A blood draw means answers without waiting for surgery, and an option when surgery is too risky.
Focused by design. Complete in what it delivers.
STb is optimised for speed and actionability. Here is exactly what is included — and what to step up for.
Included
- SNVs & InDels: High-depth analysis across 33 highly actionable genes
- Fusions: Across 13 genes known for clinically actionable rearrangements
- PGx Panel: 35-gene Pharmacogenomics & Drug-Response Panel
- Immune Profile: TMB and MSI via an adhoc 200+ gene test
- Tumour-Fraction (TFx): The proportion of blood DNA shedding from the tumour
Excluded from the primary panel
- Broad copy-number (CNV) and full mutational-signature analysis — these need a wider primary panel
- Full trial-matching reach — step up to STb O+ for the fullest picture
33 genes. 13 fusions. Highly actionable.
Every gene in this panel was selected because it has a direct, accessible drug or trial match in India.
Even on a fast-tracked panel, we never hand back raw data.
The engine gives your oncologist an action plan — immediately.
Immediate Drug Matching
Detected mutations mapped to targeted therapies physically accessible in India today.
Biosimilar Mapping
Where an expensive therapy is indicated, we pair it with clinically-equivalent, CDSCO-approved biosimilars to reduce cost.
Resistance Flagging
Variants (e.g. specific TP53 or KRAS changes) that cause resistance to standard therapies, so your doctor can pivot immediately.
Four steps to an actionable answer.
From blood draw to action plan — fast-tracked for urgent decisions.
Urgent Sample Collection
A specialised blood draw by a qualified phlebotomist, at home or in clinic. (Kits are for phlebotomist use only — not for self-testing.)
Rapid Sequencing
Cell-free DNA is extracted and sequenced on a fast-tracked next-generation pipeline.
Actionable Translation
The engine maps targets exclusively to drugs currently accessible in India.
Medical Board & Delivery
A medical oncologist signs off, and your navigator helps execute the plan immediately.
₹1,50,000 — panel + execution bundle.
The price includes the testing panel and the execution bundle: the Blueprint Care decision report with three months of care coordination, plus an in-person KPCIRC molecular tumour board review to turn your results into an immediate treatment roadmap.
Regulatory information & critical limitations
Results must always be interpreted by a qualified healthcare professional alongside your full clinical history.
● Test boundaries. A normal result means the tumour does not carry these 33 specific actionable mutations. It does not mean the cancer is gone, nor rule out changes in the other ~20,000 genes in the body.
● DNA-shedding variables. Not all cancers release enough DNA into blood to be detected by liquid biopsy.
● Clonal haematopoiesis. Occasionally, detected changes originate from normal ageing blood cells, not the tumour.
The science behind this
The Signature STb approach — focused, blood-based genotyping to guide immediate therapy — is supported by liquid-biopsy evidence.
Study 1 · Plasma genotyping speeds matched therapy
In advanced lung cancer, adding plasma ctDNA genotyping to tissue increased the number of patients found to have a targetable alteration and able to start matched therapy.
Study 2 · Blood CGP is validated and guideline-backed
Blood-based comprehensive genomic profiling has been validated in large studies, and guidelines endorse ctDNA testing when tissue is limited or a faster answer is needed.
Need a second opinion or professional feedback? If you want an independent clinical view — or you are a clinician seeking a molecular tumour board discussion — our exclusive clinical partner KPCIRC provides paid second opinions, molecular tumour board reviews, and genetic counselling. Ask your navigator, or request it from any page.
The words you will see, in plain language.
What we DO
- Find directly-actionable drivers and fusions, fast
- Include an immune profile (TMB, MSI via a 200+ gene adhoc test) and PGx
- Map targets to India-accessible drugs and biosimilars
- Flag resistance variants so your team can pivot
What we DON'T do
- Diagnose cancer or decide treatment alone
- Report broad copy-number changes (step up for that)
- Rule out disease from a normal result
- Guarantee a drug's availability, approval, cover, or benefit
Signature STb is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →